Relive the excitement of the Patriots’ path to their fourth Super Bowl Championship with “Pumped”, a special commemorative book from The Boston Globe. Order now.

Verastem begins inhibitor compound trial

Robert Forrester is the president of Verastem.

Pat Greenhouse/Globe Staff/File

Robert Forrester is the president of Verastem.

Cambridge-based Verastem Inc., which focuses on developing drugs to treat cancer by the targeted killing of cancer stem cells, said Wednesday it has initiated a phase 1 trial of VS-4718, a novel, small molecule inhibitor of focal adhesion kinase, in patients with advanced cancer. The study will enroll up to 40 patients at three US locations. Verastem president and chief operating officer Robert Forrester said VS-4718 is the second compound in the company’s portfolio to enter clinical development.

Loading comments...

Wake up with today's top stories.

Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
or
Please enter a valid email
BostonGlobe.com will never post anything without asking. Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com